Showing results (271-280 of 419) with videos related to
Sort By:
Pageof 42
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.JCO Precision Oncology|April 30, 2026
Pertuzumab and Trastuzumab in Patients With ERBB2/3-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry StudyJohn K Chan, Michael Rothe, Elizabeth Garrett-Mayer, et al.Oncotargets and Therapy|May 17, 2021
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid MalignanciesSarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway AberrationsThereasa A Rich, Karen L Reckamp, Young Kwang Chae, et al.Journal for Immunotherapy of Cancer|April 14, 2021
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancersRivka R Colen, Christian Rolfo, Murat Ak, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2019
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation TrialVivek Subbiah, Pete M Anderson, Kalevi Kairemo, et al.JCO Precision Oncology|September 14, 2020
Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNANora S Sánchez, Michael P Kahle, Ann Marie Bailey, et al.Cancer|March 7, 2023
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumorsFilip Janku, Milind M Javle, Shiraj Sen, et al.Journal for Immunotherapy of Cancer|July 28, 2021
Author response to Cunha et alRivka R Colen, Christian Rolfo, Murat Ak, et al.JCO Precision Oncology|July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced CancersMohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.Pageof 42